A number of other firms have also recently commented on MYGN. Analysts at Cowen upgraded shares of Myriad Genetics from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, April 20th. Analysts at Zacks reiterated a “neutral” rating on shares of Myriad Genetics in a research note to investors on Friday, February 10th. They now have a $25.00 price target on the stock.
Myriad Genetics opened at 26.45 on Wednesday. Myriad Genetics has a 52-week low of $17.51 and a 52-week high of $27.00. The company has a market cap of $2.229 billion and a price-to-earnings ratio of 21.63.
The company last announced its quarterly results on Tuesday, May 1st. It reported $0.34 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.32 EPS by $0.02. The company’s quarterly revenue was up 26.8% on a year-over-year basis. Analysts expect that Myriad Genetics will post $0.33 EPS next quarter.
Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests.